Invesaro

Stocks Comparison

Abbott Laboratories vs Pfizer: revenue, profit, margins and growth compared

Abbott Laboratories brought in $44.3B of revenue in fiscal 2025, Pfizer $62.6B in fiscal 2025. Revenue changed by +5.7% at Abbott Laboratories and -1.6% at Pfizer on the year before, so Abbott Laboratories grew faster. Abbott Laboratories kept 14.7% of its revenue as net profit, Pfizer 12.4%. Free cash flow was $7.4B at Abbott Laboratories and $9.1B at Pfizer.

Side by side, latest fiscal year

ABTPFE
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$44.3B$62.6B
Revenue growth+5.7%-1.6%
Net income$6.5B$7.8B
Net margin14.7%12.4%
Free cash flow$7.4B$9.1B
Free cash flow margin16.7%14.5%
Earnings per share (diluted)$3.72$1.36
Cash$8.5B$1.1B
Debt$12.9B$64.6B
Price to earnings27.221.1
Market value$175.3B$163.4B
Dividend yield2.37%6.00%
Rank by revenue in sector#18 of 523 · Health care#13 of 523 · Health care

Over the years

Revenue
ABT FY2018: $30.6BABT FY2019: $31.9BABT FY2020: $34.6BABT FY2021: $43.1BABT FY2022: $43.7BABT FY2023: $40.1BABT FY2024: $42BABT FY2025: $44.3BPFE FY2018: $40.8BPFE FY2019: $40.9BPFE FY2020: $41.7BPFE FY2021: $81.3BPFE FY2022: $101.2BPFE FY2023: $59.6BPFE FY2024: $63.6BPFE FY2025: $62.6BFY18FY19FY20FY21FY22FY23FY24FY25
ABT $44.3BPFE $62.6B
Net income
ABT FY2018: $2.4BABT FY2019: $3.7BABT FY2020: $4.5BABT FY2021: $7.1BABT FY2022: $6.9BABT FY2023: $5.7BABT FY2024: $13.4BABT FY2025: $6.5BPFE FY2018: $11.2BPFE FY2019: $16BPFE FY2020: $9.2BPFE FY2021: $22BPFE FY2022: $31.4BPFE FY2023: $2.1BPFE FY2024: $8BPFE FY2025: $7.8BFY18FY19FY20FY21FY22FY23FY24FY25
ABT $6.5BPFE $7.8B
Net margin
ABT FY2018: 7.7%ABT FY2019: 11.6%ABT FY2020: 13.0%ABT FY2021: 16.4%ABT FY2022: 15.9%ABT FY2023: 14.3%ABT FY2024: 31.9%ABT FY2025: 14.7%PFE FY2018: 27.3%PFE FY2019: 39.2%PFE FY2020: 22.0%PFE FY2021: 27.0%PFE FY2022: 31.0%PFE FY2023: 3.6%PFE FY2024: 12.6%PFE FY2025: 12.4%FY18FY19FY20FY21FY22FY23FY24FY25
ABT 14.7%PFE 12.4%
Revenue growth
ABT FY2019: +4.3%ABT FY2020: +8.5%ABT FY2021: +24.5%ABT FY2022: +1.3%ABT FY2023: -8.1%ABT FY2024: +4.6%ABT FY2025: +5.7%PFE FY2019: +0.2%PFE FY2020: +1.8%PFE FY2021: +95.2%PFE FY2022: +24.5%PFE FY2023: -41.1%PFE FY2024: +6.8%PFE FY2025: -1.6%FY19FY20FY21FY22FY23FY24FY25
ABT +5.7%PFE -1.6%
Free cash flow
ABT FY2018: $4.9BABT FY2019: $4.5BABT FY2020: $5.7BABT FY2021: $8.6BABT FY2022: $7.8BABT FY2023: $5.1BABT FY2024: $6.4BABT FY2025: $7.4BPFE FY2018: $13.8BPFE FY2019: $10.5BPFE FY2020: $12.2BPFE FY2021: $29.9BPFE FY2022: $26BPFE FY2023: $4.8BPFE FY2024: $9.8BPFE FY2025: $9.1BFY18FY19FY20FY21FY22FY23FY24FY25
ABT $7.4BPFE $9.1B

Fiscal years as each company reports them; the two may end in different months.

Questions about Abbott Laboratories and Pfizer

Which is bigger by revenue, Abbott Laboratories or Pfizer?

Pfizer is bigger by revenue: $62.6B in fiscal 2025, against $44.3B for Abbott Laboratories in fiscal 2025.

Which keeps more of its revenue as profit, Abbott Laboratories or Pfizer?

Abbott Laboratories had a net margin of 14.7% in fiscal 2025; Pfizer had 12.4% in fiscal 2025.

Which grew revenue faster, Abbott Laboratories or Pfizer?

In their latest fiscal years revenue changed by +5.7% at Abbott Laboratories and -1.6% at Pfizer.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies